Inhibikase Therapeutics Inc (IKT)
SG&A Expense Growth
107.01%
Fiscal year · Period ending:
IKT SG&A Expense Growth
Latest reported107.01%period ending
Latest reported107.01%period ending
IKT FY SG&A Growth (YoY) (0.00% → 107.01%)
Latest values, visible window
High-resolution chart · PNG
IKT sg&a expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 107.0136% | |
| 69.0228% | |
| 8.399% | |
| 0% | |
| 0% | |
| 0% | |
| -100% | |
| 254.1746% | |
| -3.2566% | |
| 0% |